Redeye provides an update following Scandinavian Chemotech’s Q1 2026 report. Sales were softer than expected, while the solid cost control continued. As a result, we have trimmed our sales estimates, while doing the same for OPEX. All in all, we arrive at a reiterated fair value range of SEK2-10, with a base case of SEK6.3.
LÄS MER
